Barclays
DNTH icon

Barclays’s Dianthus Therapeutics DNTH Stock Holding History

Barclays’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.9M Buy
379,606
+203,306
+115% +$11.8M 0.01% 905
2025
Q4 		$7.27M Sell
176,300
-28,069
-14% -$1.09M ﹤0.01% 1938
2025
Q3 		$8.04M Buy
204,369
+139,548
+215% +$3.57M ﹤0.01% 1835
2025
Q2 		$1.21M Buy
64,821
+33,680
+108% +$632K ﹤0.01% 3210
2025
Q1 		$565K Sell
31,141
-11,625
-27% -$256K ﹤0.01% 3449
2024
Q4 		$932K Buy
42,766
+1,082
+3% +$27.8K ﹤0.01% 3417
2024
Q3 		$1.14M Buy
41,684
+33,185
+390% +$924K ﹤0.01% 3273
2024
Q2 		$220K Sell
8,499
-5,904
-41% -$142K ﹤0.01% 3530
2024
Q1 		$432K Buy
14,403
+14,400
+480,000% +$313K ﹤0.01% 3681
2023
Q4 		$31 Buy
+3
New +$33 ﹤0.01% 5188
2023
Q3 		– Sell
-3
Closed -$39 – 4620
2023
Q2 		$39 Hold
3
– – ﹤0.01% 4469
2023
Q1 		$41 Sell
3
-330
-99% -$3.65K ﹤0.01% 5015
2022
Q4 		$2.1K Sell
333
-120
-26% -$2.12K ﹤0.01% 5081
2022
Q3 		$10K Sell
453
-87
-16% -$2.38K ﹤0.01% 4294
2022
Q2 		$10K Sell
540
-287
-35% -$7.09K ﹤0.01% 4619
2022
Q1 		$38K Sell
827
-1,966
-70% -$107K ﹤0.01% 4220
2021
Q4 		$198K Buy
2,793
+1,505
+117% +$151K ﹤0.01% 3568
2021
Q3 		$151K Sell
1,288
-354
-22% -$41.2K ﹤0.01% 3745
2021
Q2 		$257K Sell
1,642
-552
-25% -$101K ﹤0.01% 3434
2021
Q1 		$415K Sell
2,194
-224
-9% -$37.7K ﹤0.01% 3287
2020
Q4 		$304K Buy
2,418
+267
+12% +$30.3K ﹤0.01% 3538
2020
Q3 		$233K Buy
2,151
+788
+58% +$93.4K ﹤0.01% 3745
2020
Q2 		$164K Buy
1,363
+823
+152% +$116K ﹤0.01% 4207
2020
Q1 		$55K Sell
540
-665
-55% -$123K ﹤0.01% 5170
2019
Q4 		$292K Buy
1,205
+572
+90% +$107K ﹤0.01% 4747
2019
Q3 		$104K Sell
633
-392
-38% -$74.5K ﹤0.01% 5448
2019
Q2 		$242K Buy
1,025
+507
+98% +$125K ﹤0.01% 4939
2019
Q1 		$137K Buy
518
+352
+212% +$60.7K ﹤0.01% 5102
2018
Q4 		$15K Buy
166
+71
+75% +$9.68K ﹤0.01% 6019
2018
Q3 		$18K Buy
+95
New +$20K ﹤0.01% 6493

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Barclays's DNTH Position: Q1 2026 in Review

Barclays increased its Dianthus Therapeutics (DNTH) stake by 115% in Q1 2026, buying an estimated $11.8M and bringing the position to 379,606 shares worth $31.9M. The position accounts for 0.01% of the portfolio, ranked #905.

Barclays first reported a position in DNTH in Q3 2018 and has held it in 30 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Barclays held 379,606 shares of Dianthus Therapeutics worth $31.9M as of Q1 2026.
  • Barclays bought 203,306 Dianthus Therapeutics shares in Q1 2026, an estimated $11.8M.
  • Dianthus Therapeutics made up 0.01% of Barclays's portfolio in Q1 2026, its #905 holding.
  • Barclays first reported a position in Dianthus Therapeutics in Q3 2018 and has held it in 30 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.